Azenta Reports Mixed Q3 2025 Results with Improved Operational Efficiency Amid Rising Net Losses

Azenta, Inc. (NASDAQ: AZTA) reported its financial results for the three and nine months ending June 30, 2025, revealing trends in revenue, expenses, and overall company health.

Key Points and Statistics:

• Total revenue: $143.94 million for Q3 2025 vs. $144.29 million in Q3 2024; a flat performance.
• Revenue growth for nine months: Increased by 3% to $434.87 million from $422.37 million YoY.
• Products revenue: Decreased by 10% to $39.39 million for Q3 2025.
• Services revenue: Increased 4% to $104.56 million for Q3 2025.
• Gross profit: Increased 3.5% to $67.76 million in Q3 2025.
• Operating expenses: Decreased from $72.58 million in Q3 2024 to $68.47 million in Q3 2025, largely due to reduced R&D expenses.
• Operating loss: $714,000 in Q3 2025, a significant improvement from a $7.11 million loss in Q3 2024.
• Net loss: $52.81 million for Q3 2025, compared to $6.58 million in Q3 2024, primarily from losses related to discontinued operations.
• Income tax expense: Increased significantly to $2.76 million for Q3 2025 from $600,000 in Q3 2024, influenced by a $6.5 million tax impact from repatriation of overseas earnings.
• Transformation costs: Totaled $1.54 million in Q3 2025, part of a strategic initiative focusing on efficiency across operations.
• Cash position: Cash and cash equivalents were $270.04 million as of June 30, 2025, slightly down from $280.03 million a year earlier.

Positive Aspects:

• Improvement in operating loss, signaling greater operational efficiency.
• Increase in gross profit margin relative to the prior fiscal year.
• Significant revenue growth in Multiomics services.
• Strategic plans to simplify portfolio through the planned sale of the B Medical Systems business.

Negative Aspects:

• Overall net loss expanding, attributed to substantial losses from discontinued operations.
• Continued higher tax expenses impacting net income, signaling urgency for tax planning and optimization.
• Lower revenue from the Sample Management Solutions segment, particularly in core product lines.

In summary, while Azenta, Inc. displays recovery signs in operational efficiencies and profit margins, external challenges including ongoing losses from divested operations and elevated tax expenses continue to affect its overall financial outlook.